Advanced Human Imaging (ASX:AHI) - CoFounder and Head of Strategy, Vlado Bosanac
CoFounder and Head of Strategy, Vlado Bosanac
Source: AHI
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Advanced Human Imaging (AHI) announces it will commence US presentations to raise US$15 million (nearly A$20 million)
  • The health imaging company is aiming to list on the NASDAQ, after filing a Form F-1 with the US Securities and Exchange Commission
  • AHI has now received conditional approval from the Nasdaq to list its American Depositary Shares (ADS)
  • The filing is based on an assumed ratio of one ADS to nine ordinary shares of AHI
  • On the market today, AHI was down 10.3 per cent and is trading at $1.01 per share

Advanced Human Imaging (AHI) has announced it will commence US presentations to raise US$15 million (nearly A$20 million).

The health imaging company is aiming to list on the NASDAQ, after filing a Form F-1 with the US Securities and Exchange Commission.

AHI has now received conditional approval from the Nasdaq to list its American Depositary Shares (ADS), each of which will represent a determined number of ordinary shares of AHI.

Final approval of the listing is subject to the company paying the Nasdaq listing fee and fulfilling the remaining conditions as needed by Nasdaq.

Additionally, AHI has submitted an updated public filing of a registration statement on Form F-1, with the US Securities and Exchange Commission.

The updated filings is for the proposed initial US public offering of its ADS. The number of securities to be sold and the price per ADS for the offering have been outlined in the F-1, based on a price range of US$7 to US$9 (about A$9 to A$12).

The filing was based on an assumed ADS to ordinary share ratio of one (1) ADS representing nine (9) ordinary shares of AHI.

On the market today, AHI was down 10.7 per cent, trading at $1.00 per share at 1:20 pm AEDT.

AHI by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…